What is your preferred second-line treatment for high-grade neuroendocrine carcinoma of GI origin after progression on carboplatin + etoposide?

This is a great question. I will try to summarize the current data for treating poorly differentiated GEP-NEC.

• However, high-grade poorly differentiated GEP neuroendocrine carcinomas (GEP-NECs) are rare cancers, there is an increase in incidence estimated to be 0.2-0.5 per 100,000 inhabitants). (1-2...